Company Information & Drug Savings for ImmunoGen Medications

ImmunoGen, now part of AbbVie, pioneered antibody-drug conjugate (ADC) technology for cancer treatment. The company developed Elahere (mirvetuximab soravtansine), an ADC targeting folate receptor alpha for platinum-resistant ovarian cancer. ImmunoGen’s ADC platform enables targeted delivery of cytotoxic agents to cancer cells while minimizing damage to healthy tissue.

How to contact ImmunoGen

Address

830 Winter Street, Waltham, MA 02451

Browse medications manufactured by ImmunoGen